Kanitinib in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety , tolerability, pharmacokinetics of
Kanitinib and determine the optimal dose in patients with recurrent or metastatic solid
tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Beijing Konruns Pharmaceutical Co., Ltd.
Collaborator:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences